Viaskin Peanut 250 mcg + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Oct 1, 2016 โ†’ Oct 7, 2020

About Viaskin Peanut 250 mcg + Placebo

Viaskin Peanut 250 mcg + Placebo is a phase 3 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT02916446. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02916446Phase 3Completed